RU2015101115A - Гетероароматическое циклическое производное с алкильной разветвленной цепью - Google Patents
Гетероароматическое циклическое производное с алкильной разветвленной цепью Download PDFInfo
- Publication number
- RU2015101115A RU2015101115A RU2015101115A RU2015101115A RU2015101115A RU 2015101115 A RU2015101115 A RU 2015101115A RU 2015101115 A RU2015101115 A RU 2015101115A RU 2015101115 A RU2015101115 A RU 2015101115A RU 2015101115 A RU2015101115 A RU 2015101115A
- Authority
- RU
- Russia
- Prior art keywords
- propan
- triazol
- benzamide
- ethyl
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- 150000003839 salts Chemical class 0.000 claims abstract 28
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 14
- 125000005843 halogen group Chemical group 0.000 claims abstract 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract 5
- 125000001424 substituent group Chemical group 0.000 claims abstract 5
- 125000001425 triazolyl group Chemical group 0.000 claims abstract 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 72
- -1 5-fluoropyridin-2-yl Chemical group 0.000 claims 41
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 34
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 5
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- BZXPFBYXSVHIHK-UHFFFAOYSA-N N-(triazol-2-yl)benzamide Chemical compound C(C1=CC=CC=C1)(=O)NN1N=CC=N1 BZXPFBYXSVHIHK-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000020595 eating behavior Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- XYDRZYRMVCLDNX-OYKVQYDMSA-N n-[(2s)-1-[4-(4-fluorophenyl)pyrazol-1-yl]propan-2-yl]-n-(2-hydroxypropyl)-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC(O)C)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)N(N=C1)C=C1C1=CC=C(F)C=C1 XYDRZYRMVCLDNX-OYKVQYDMSA-N 0.000 claims 1
- VPYMEHLEGRGYRR-KRWDZBQOSA-N n-[(2s)-1-[4-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-n-(2-hydroxyethyl)-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CCO)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)N(N=C1)C=C1C1=CC=C(F)C=N1 VPYMEHLEGRGYRR-KRWDZBQOSA-N 0.000 claims 1
- AUYOEDZTUTZLGZ-AWEZNQCLSA-N n-[(2s)-1-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]propan-2-yl]-n,5-dimethyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(C)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)C(N=1)=NOC=1C1=CC=C(F)C=N1 AUYOEDZTUTZLGZ-AWEZNQCLSA-N 0.000 claims 1
- GIIVJJWMFOMHDE-INIZCTEOSA-N n-ethyl-n-[(2s)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=CC=1)N1N=CC=N1)N(N=1)C=CC=1C1=CC=C(F)C=N1 GIIVJJWMFOMHDE-INIZCTEOSA-N 0.000 claims 1
- UCTMYARPCLQYDJ-KRWDZBQOSA-N n-ethyl-n-[(2s)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)N(N=1)C=CC=1C1=CC=C(F)C=N1 UCTMYARPCLQYDJ-KRWDZBQOSA-N 0.000 claims 1
- DYZJRZXHXAMQPY-KRWDZBQOSA-N n-ethyl-n-[(2s)-1-[4-(3-hydroxyphenyl)triazol-1-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)N(N=N1)C=C1C1=CC=CC(O)=C1 DYZJRZXHXAMQPY-KRWDZBQOSA-N 0.000 claims 1
- UBPQYWSKDJKHMJ-SFHVURJKSA-N n-ethyl-n-[(2s)-1-[4-(3-methoxyphenyl)triazol-1-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)N(N=N1)C=C1C1=CC=CC(OC)=C1 UBPQYWSKDJKHMJ-SFHVURJKSA-N 0.000 claims 1
- RJAPASAWWRQAGM-INIZCTEOSA-N n-ethyl-n-[(2s)-1-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)C(O1)=NN=C1C1=CC=C(F)C=C1 RJAPASAWWRQAGM-INIZCTEOSA-N 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012-135278 | 2012-06-15 | ||
| JP2012135278 | 2012-06-15 | ||
| JP2012-246834 | 2012-11-09 | ||
| JP2012246834 | 2012-11-09 | ||
| PCT/JP2013/066314 WO2013187466A1 (ja) | 2012-06-15 | 2013-06-13 | 分岐鎖アルキルヘテロ芳香環誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015101115A true RU2015101115A (ru) | 2016-08-10 |
Family
ID=49758284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015101115A RU2015101115A (ru) | 2012-06-15 | 2013-06-13 | Гетероароматическое циклическое производное с алкильной разветвленной цепью |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20150166523A1 (enExample) |
| EP (1) | EP2862855A4 (enExample) |
| JP (1) | JPWO2013187466A1 (enExample) |
| KR (1) | KR20150023390A (enExample) |
| CN (1) | CN104364238A (enExample) |
| AU (1) | AU2013275209A1 (enExample) |
| BR (1) | BR112014031109A2 (enExample) |
| CA (1) | CA2876249A1 (enExample) |
| HK (1) | HK1203197A1 (enExample) |
| IL (1) | IL236139A0 (enExample) |
| IN (1) | IN2014DN10489A (enExample) |
| MX (1) | MX2014015298A (enExample) |
| NZ (1) | NZ702635A (enExample) |
| PH (1) | PH12014502751A1 (enExample) |
| RU (1) | RU2015101115A (enExample) |
| SG (1) | SG11201408316SA (enExample) |
| TW (1) | TW201412723A (enExample) |
| WO (1) | WO2013187466A1 (enExample) |
| ZA (1) | ZA201409167B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2585806T3 (es) | 2009-10-23 | 2016-10-10 | Janssen Pharmaceutica N.V. | Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina |
| CN106243052B (zh) * | 2015-06-09 | 2020-01-21 | 广东东阳光药业有限公司 | 取代的杂环化合物及其制备方法和用途 |
| WO2017012502A1 (en) | 2015-07-17 | 2017-01-26 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| JP2018188364A (ja) * | 2015-10-02 | 2018-11-29 | 大正製薬株式会社 | 複素芳香環誘導体 |
| GB201601703D0 (en) * | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
| HRP20220642T1 (hr) | 2016-03-10 | 2022-06-24 | Janssen Pharmaceutica Nv | Postupci za liječenje depresije uporabom antagonista receptora oreksina 2 |
| US10738031B2 (en) | 2016-04-15 | 2020-08-11 | Boehringer Ingelheim International Gmbh | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity |
| EP3442963B1 (en) * | 2016-04-15 | 2020-05-06 | Boehringer Ingelheim International GmbH | N-[(pyrazinyloxy)propanyl]benzamides |
| JP6591698B2 (ja) * | 2016-04-15 | 2019-10-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なｎ−［（ピリミジニルアミノ）プロパニル］−およびｎ−［（ピラジニルアミノ）プロパニル］アリールカルボキサミド |
| US10710984B2 (en) | 2016-04-15 | 2020-07-14 | Boehringer Ingelheim International Gmbh | N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides |
| EP3442967B1 (en) | 2016-04-15 | 2020-05-13 | Boehringer Ingelheim International GmbH | Novel n-[(pyrimidinyloxy)propanyl]benzamides |
| JP6918827B2 (ja) * | 2016-04-15 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なｎ−［（ピリジルオキシ）プロパニル］ベンズアミド |
| CN106674207B (zh) * | 2016-12-09 | 2019-04-19 | 广东东阳光药业有限公司 | 取代的芳基杂芳基化合物及其用途 |
| EP3661928B1 (en) | 2017-07-31 | 2021-06-16 | Boehringer Ingelheim International GmbH | N-[(pyrimidinylamino)propanyl]-, n-[(pyridylamino)propanyl]- and n-[(pyrazinylamino)propanyl]arylcarboxamides |
| JP6874217B2 (ja) | 2017-09-28 | 2021-05-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なｎ−（２，２−ジフルオロエチル）−ｎ−［（ピリミジニルアミノ）プロパニル］アリールカルボキサミド |
| CN111909044A (zh) * | 2019-05-09 | 2020-11-10 | 南京爱德程医药科技有限公司 | 2-(烷基氨基)乙基苯甲酸酯类化合物的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| CA2520870A1 (en) * | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| WO2008062878A1 (fr) * | 2006-11-22 | 2008-05-29 | Nihon Nohyaku Co., Ltd. | Nouveau dérivé de pyrazole, agent de lutte contre des organismes nuisibles et utilisation de l'agent de lutte contre des organismes nuisibles |
| EP2131654A4 (en) * | 2007-03-02 | 2011-02-02 | Merck Sharp & Dohme | Bipyridine-carboxamide-orexin receptor Antagonist |
| CA2695621A1 (en) * | 2007-08-09 | 2009-02-12 | Merck Sharp & Dohme Corp. | Pyridine carboxamide orexin receptor antagonists |
| WO2010044054A1 (en) * | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
| AU2009307916A1 (en) * | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| CA2741648A1 (en) * | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| EP2350010B1 (en) * | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| US20130281465A1 (en) * | 2010-12-17 | 2013-10-24 | Taisho Pharmaceutical Co., Ltd. | Pyrazole derivative |
| EP2708537A4 (en) * | 2011-05-10 | 2014-10-01 | Taisho Pharmaceutical Co Ltd | HETEROAROMATIC RING DERIVATIVE |
| JP2015131802A (ja) * | 2013-12-13 | 2015-07-23 | 大正製薬株式会社 | 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬 |
-
2013
- 2013-06-13 HK HK15103741.9A patent/HK1203197A1/xx unknown
- 2013-06-13 JP JP2014521400A patent/JPWO2013187466A1/ja not_active Withdrawn
- 2013-06-13 CN CN201380031392.1A patent/CN104364238A/zh active Pending
- 2013-06-13 AU AU2013275209A patent/AU2013275209A1/en not_active Abandoned
- 2013-06-13 WO PCT/JP2013/066314 patent/WO2013187466A1/ja not_active Ceased
- 2013-06-13 BR BR112014031109A patent/BR112014031109A2/pt not_active IP Right Cessation
- 2013-06-13 CA CA2876249A patent/CA2876249A1/en not_active Abandoned
- 2013-06-13 MX MX2014015298A patent/MX2014015298A/es unknown
- 2013-06-13 KR KR20147035123A patent/KR20150023390A/ko not_active Withdrawn
- 2013-06-13 US US14/407,326 patent/US20150166523A1/en not_active Abandoned
- 2013-06-13 IN IN10489DEN2014 patent/IN2014DN10489A/en unknown
- 2013-06-13 SG SG11201408316SA patent/SG11201408316SA/en unknown
- 2013-06-13 NZ NZ702635A patent/NZ702635A/en not_active IP Right Cessation
- 2013-06-13 EP EP13804194.2A patent/EP2862855A4/en not_active Withdrawn
- 2013-06-13 RU RU2015101115A patent/RU2015101115A/ru not_active Application Discontinuation
- 2013-06-14 TW TW102121129A patent/TW201412723A/zh unknown
-
2014
- 2014-12-08 IL IL236139A patent/IL236139A0/en unknown
- 2014-12-09 PH PH12014502751A patent/PH12014502751A1/en unknown
- 2014-12-12 ZA ZA2014/09167A patent/ZA201409167B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014031109A2 (pt) | 2017-06-27 |
| NZ702635A (en) | 2016-11-25 |
| TW201412723A (zh) | 2014-04-01 |
| CN104364238A (zh) | 2015-02-18 |
| SG11201408316SA (en) | 2015-03-30 |
| WO2013187466A1 (ja) | 2013-12-19 |
| MX2014015298A (es) | 2015-03-05 |
| PH12014502751A1 (en) | 2015-02-09 |
| IN2014DN10489A (enExample) | 2015-08-21 |
| HK1203197A1 (en) | 2015-10-23 |
| ZA201409167B (en) | 2016-03-30 |
| KR20150023390A (ko) | 2015-03-05 |
| EP2862855A4 (en) | 2015-11-18 |
| EP2862855A1 (en) | 2015-04-22 |
| AU2013275209A1 (en) | 2015-01-22 |
| CA2876249A1 (en) | 2013-12-19 |
| JPWO2013187466A1 (ja) | 2016-02-08 |
| IL236139A0 (en) | 2015-02-01 |
| US20150166523A1 (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013132930A (ru) | Производное пиразола | |
| RU2458920C2 (ru) | Новые соединения | |
| RU2486181C2 (ru) | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ | |
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| AR074426A1 (es) | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende | |
| JP2008110984A5 (enExample) | ||
| JP2013532727A5 (enExample) | ||
| RU2016106774A (ru) | Фамацевтическая композиция, содержащая соединение пиримидина, как действующий ингредиент | |
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| RU2015154987A (ru) | Гетероциклические производные | |
| JP2015500862A5 (enExample) | ||
| RU2014103587A (ru) | Производные циклических аминов в качестве антагонистов рецептора ер4 | |
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| RU2014132044A (ru) | Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars) | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| RU2017126187A (ru) | 5-[(пиперазин-1-ил)-3-оксо-пропил]-имидазолидин-2,4-дионовые производные в качестве ингибиторов adamts для лечения остеоартрита | |
| RU2014130214A (ru) | Пиримидин-2, 4-диаминовые производные в качестве ингибиторов киназы | |
| RU2019136279A (ru) | C5 -Анилинохиназолиновые соединения и их использование в лечении рака | |
| RU2011140869A (ru) | Пиперазиновое соединение, ингибирующее простагландин-d-синтазу | |
| JP2013523814A5 (enExample) | ||
| RU2017103953A (ru) | Пестицидно активные гетероциклические производные с серосодержащими заместителями | |
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| JP2016523976A5 (enExample) | ||
| RU2017107521A (ru) | Замещенные производные азетидина в качестве лигандов рецепторов следовых аминов taar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170829 |